InterLink Biotechnologies LLC, Virtual Drug Discovery Inc., Wyeth deal

Virtual Drug will access InterLink's IP and expertise related to peptides that have increased stability and resistance to protease degradation for animal and human product development. Virtual Drug will pay access fees to InterLink, which will be eligible for milestones and royalties on resulting products. InterLink retains rights for use of resulting products in crop protection, for which Virtual Drug is eligible for royalties. ...